Graham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., . . . Fakih, M. G. (2016). Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical therapeutics, 38(6), 1376-1391. https://doi.org/10.1016/j.clinthera.2016.03.023
Chicago-Zitierstil (17. Ausg.)Graham, Christopher N., Gregory A. Maglinte, Lee S. Schwartzberg, Timothy J. Price, Hediyyih N. Knox, Guy Hechmati, Jonas Hjelmgren, Beth Barber, und Marwan G. Fakih. "Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy." Clinical Therapeutics 38, no. 6 (2016): 1376-1391. https://doi.org/10.1016/j.clinthera.2016.03.023.
MLA-Zitierstil (9. Ausg.)Graham, Christopher N., et al. "Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy." Clinical Therapeutics, vol. 38, no. 6, 2016, pp. 1376-1391, https://doi.org/10.1016/j.clinthera.2016.03.023.